Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, USA.
Sanofi, Research and Development, Bridgewater, NJ, USA.
Arthritis Res Ther. 2023 May 27;25(1):88. doi: 10.1186/s13075-023-03068-w.
To evaluate baseline hemoglobin (Hb) and radiographic progression over time in patients enrolled in the Brigham and Women's Rheumatoid Arthritis Sequential Study (BRASS) registry.
The BRASS is a prospective observational registry of patients with rheumatoid arthritis. BRASS Hb data and total sharp score data were matched with the main BRASS patients. Hb at baseline was categorized per the World Health Organization guidelines. Mean Hb, mean total sharp score, and mean changes over time from baseline to month 120 were summarized (overall, by low/normal Hb, and by current medication at baseline). All analyses were descriptive.
Out of the total (N = 1114) rheumatoid arthritis patients included in the analysis, patients with low Hb at baseline (n = 224 [20%]) had longer disease duration and higher disease activity and reported more pain compared with patients with normal Hb at baseline (n = 890 [80%]). Patients with low Hb at baseline continued to have lower Hb than patients with normal Hb throughout 10 years; although, on average, patients in the low Hb subgroup exhibited a steady increase in Hb levels. A larger increase in total sharp score over time was observed for patients with low Hb than for patients with normal Hb. No meaningful differences potentially attributable to medication at baseline were detected.
Patients with low Hb levels at baseline tended to have increased radiographic progression as measured by total sharp score compared with patients with rheumatoid arthritis having normal Hb levels. Patients with low Hb experienced sustained improvements in Hb levels over time, regardless of the class of medication used.
ClinicalTrials.gov NCT01793103.
评估入组 Brigham 和妇女类风湿关节炎序贯研究（BRASS）登记处的患者的基线血红蛋白（Hb）和随时间推移的放射学进展。
BRASS 是一项前瞻性观察性类风湿关节炎患者登记处。BRASS 的 Hb 数据和总锐利评分数据与主要 BRASS 患者相匹配。根据世界卫生组织指南对基线 Hb 进行分类。总结了基线时的平均 Hb、平均总锐利评分以及从基线到 120 个月的平均变化（总体情况、低/正常 Hb 以及基线时的当前药物治疗情况）。所有分析均为描述性分析。
在纳入分析的 1114 例类风湿关节炎患者中，基线时 Hb 较低的患者（n=224[20%]）疾病持续时间更长，疾病活动度更高，且与基线时 Hb 正常的患者（n=890[80%]）相比，报告的疼痛更多。基线时 Hb 较低的患者在 10 年内始终保持低于基线时 Hb 正常的患者；尽管，平均而言，Hb 较低亚组的患者 Hb 水平呈稳步上升趋势。Hb 较低的患者总锐利评分随时间的推移而增加，而 Hb 正常的患者则不然。未发现可能归因于基线时药物的有意义差异。
与基线时 Hb 水平正常的类风湿关节炎患者相比，基线时 Hb 水平较低的患者的总锐利评分测量的放射学进展趋势更大。无论使用何种药物类别，Hb 水平较低的患者随着时间的推移，Hb 水平持续改善。
ClinicalTrials.gov NCT01793103。
